Even though mPD-L1 is a commonly used biomarker for both prognosis and response to anti-PD-1/PD-L1 treatment in cancer, controversy remains over the predictive and prognostic utility of mPD-L1 positivity. This evidence concerns the gene PDCD1 and cancer.